The pharmacologic treatment of Dravet syndrome
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Dravet syndrome (DS) is one of the most pharmacoresistant epilepsy syndromes. Valproate is used as a first‐line agent to prevent the recurrence of febrile seizures and oral/nasal/rectal benzodiazepine is used for any long‐lasting seizures, but these agents are most often insufficient. Lamotrigine, carbamazepine, and high doses of intravenous phenobarbital should be avoided because they may worsen seizures. Topiramate, levetiracetam, bromide, and the ketogenic diet may provide substantial efficacy as adjunctive therapy/procedure. Stiripentol is the only compound that proved its efficacy in DS through two independent randomized placebo‐controlled trials, when combined with valproate and clobazam. Their dose has to be decreased to minimize the side effects (mostly loss of appetite) resulting from pharmacokinetic interactions of stiripentol powerfully inhibiting cytochromes P450. Stiripentol acts as a γ‐aminobutyric acid (GABA)ergic agent, mainly via the α3 subunit of GABA A receptors. Stiripentol (Diacomit) was approved as an orphan drug in 2007 in Europe for adjunctive therapy in DS. Up to now, >500 children have been safely treated, and recent experiment in Japan confirmed stiripentol benefit in DS children with comedications other than valproate and clobazam. Because early status epilepticus is likely to negatively impact cognitive outcome, we recommend the introduction of stiripentol as soon as the diagnosis of DS is clinically confirmed. Topiramate and the ketogenic diet are alternatives in pharmacoresistant cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173 · cited 1×
“Animal models of DS are now available (Yu et al., 2006; Oakley et al., 2009) that should prevent exposing human patients to unnecessary cognitive studies.”
BackgroundChiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568 · cited 2×
“STP efficacy in children with DS was first suspected in one open exploratory trial (10 of 20 responders; Perez et al., 1999) and then confirmed in two randomized placebo-controlled trials, independently conducted in France and Italy (Chiron et al., 2000).”
BackgroundResultSelf-citationLamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467 · cited 2×
“…identified, namely lamotrigine that involves up to 80% of the patients, although with the very progressive introduction of this compound several weeks may be required to disclose the effect (Guerrini et al., 1998); carbamazepine and vigabatrin worsening is in the order of 60% (Thanh et al., 2002).”
BackgroundSelf-citationStiripentol: Efficacy and Tolerability in Children with Epilepsy
Perez, J., Chiron, C., Musial, C., Rey, E., Blehaut, H., D'Athis, P., Vincent, J., & Dulac, O. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02048.x · Cited by 148
Self-citation
Cited by
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 627
The genetic landscape of the epileptic encephalopathies of infancy and childhood
McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A., & Scheffer, I. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00250-1 · Cited by 604
Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies
Oyrer, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petrou, S., & Reid, C. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014456 · Cited by 315
The hidden genetics of epilepsy—a clinically important new paradigm
Thomas, R. H., & Berkovic, S. F. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.62 · Cited by 297
Wirrell, E. C., Laux, L., Donner, E., Jette, N., Knupp, K., Meskis, M. A., Miller, I., Sullivan, J., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 283
Metadata
- Authors
- Chiron, C., & Dulac, O.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 52
- Issue
- s2
- Pages
- 72-75
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1806230115
- Cited by
- 150
- References
- 4
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacologic treatment of Dravet syndrome. https://app.cochat.ai/papers/10.1111/j.1528-1167.2011.03007.x
- The paper
- Chiron, C., & Dulac, O. (2011). The pharmacologic treatment of Dravet syndrome. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03007.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.